Upgrades, downgrades, and outlook changes from major analysts.
Coverage of analyst actions including upgrades, downgrades, initiations, and price-target changes. This category tracks how institutional research influences market perception, momentum shifts, and short-term price behavior.
3,519 total articles
UBS has reaffirmed its Neutral rating on Advance Auto Parts and maintained a $65.00 price target. The firm notes the retailer's turnaround has shown sporadic progress and may require more time to reach long-term goals amid a challenging macroeconomic backdrop and tariff-related pressures. Shares have rallied recently but UBS views upside and downsi…
UBS kept a Neutral recommendation on Opendoor Technologies and raised its price target to $5.00 from $1.60 following the company's recent earnings, which the firm described as "another reset point." The new target is marginally above the stock's trading level of $4.97, even as underlying results show a revenue decline and an elevated last-twelve-mo…
UBS has raised its 12-month price target for Newell Brands Inc to $5.00 from $4.50 while leaving its rating at Neutral. The upgrade reflects an 11% increase in the firm’s target price but stops short of a more bullish stance as UBS and other brokers note the company’s continuing difficulty delivering consistent growth. Recent quarter results and a …
Melius Research downgraded Microsoft from Buy to Hold, reducing its price target to $430 and raising questions about the company’s ability to compete in artificial intelligence without a sizeable lift in capital expenditures. The firm highlighted pressure on Microsoft 365 from AI, valuation stretchedness at 49 times fiscal 2027 enterprise value to …
BMO Capital raised its price objective on CMS Energy to $80 from $79 on Monday while reiterating an Outperform rating. The move follows fiscal 2025 earnings that modestly exceeded management guidance and notable revenue growth, alongside an expanded five-year capital plan intended to support the higher end of long-term EPS targets. Regulatory quest…
UBS reduced its 12-month price target for Estée Lauder to $107 from $119 while retaining a Neutral rating, flagging concerns about management’s top-line guidance and the stock’s stretched valuation. Multiple broker actions and recent company developments - including modest quarterly sales growth, an investment in a Mexican fragrance brand and a new…
Goldman Sachs increased its price target on Flowserve Corp. to $88 while keeping a Neutral rating, citing greater confidence in margin durability and conversion of longer-cycle backlog after the company's stronger-than-expected fourth-quarter 2025 results and optimistic 2026 guidance. The shares have surged in recent months, pushing valuation metri…
Goldman Sachs has kept a Neutral rating and an $85 price target on Arrowhead Pharmaceuticals (NASDAQ:ARWR), citing the company's recent move into the commercial phase following Redemplo approval for FCS and a slate of potential clinical catalysts in 2026. The bank highlighted a Phase 3 plozasiran SHASTA3/4 readout in severe hypertriglyceridemia exp…
UBS raised its price target on Under Armour, Inc. (UAA) to $11.00 from $8.00 and kept a Buy rating, pointing to the value of the Under Armour brand and expectations that strategic initiatives will lift North America revenue growth. The move comes amid a series of analyst target adjustments and a notable 22.2% stake disclosed by Fairfax Financial. I…
UBS increased its 12-month price target for Tapestry Inc. (TPR) to $141 from $125 while retaining a Neutral rating. The firm pointed to a revitalized Coach brand and improved cost structure as drivers of stronger brand momentum, but noted that much of the positive outlook appears priced in amid elevated valuation metrics and expectations that Coach…
BMO Capital has raised its price target for Biogen Inc. to $196 from $165 while keeping a Market Perform rating, pointing to increased confidence in high-dose Spinraza and anticipated litifilimab trial readouts in systemic lupus erythematosus. The firm balanced that optimism against an expected decline in multiple sclerosis revenue in 2026 and mixe…
UBS raised its price target on Philip Morris to $181.50 from $158.00 while retaining a Neutral rating. The firm highlighted a modest fourth-quarter EPS beat, stable ZYN and IQOS volumes, and fiscal 2026 EPS guidance that tops consensus, but flagged growth metrics that sit slightly below the company’s mid-term algorithm and guidance that could tempe…
BMO Capital raised its 12-month price objective on NOV Inc. to $20 from $19 while retaining a Market Perform rating following the company's fourth-quarter 2025 results. The move comes amid a mixed set of revisions for 2026 — slightly higher revenue guidance but little change to EBITDA and lower EPS expectations due to higher taxes — and against a b…
Morgan Stanley trimmed its price target on Mettler-Toledo to $1,475 from $1,550 while retaining an Equalweight rating. The reduction follows a revision to the comparative Core Tools peer group and a move to a 25x 2026 EV/EBITDA target multiple. Other brokerages have recently issued higher targets and positive ratings after the company reported stro…
UBS has reiterated a Buy rating and a $77.00 price target on Birkenstock Holding plc ahead of the company’s first-quarter earnings release scheduled for February 12. The bank expects results broadly in line with company pre-announcements and does not foresee a revision to the fiscal 2026 outlook. Multiple other firms and rating agencies have also r…
BMO Capital Partners reduced its 12-month price target for GrafTech (EAF) to $10 from $15 while maintaining a Market Perform rating, citing a Q4 2025 earnings miss and a mixed outlook for 2026. The stock has tumbled sharply in the last week and the company reported deeply negative profitability metrics over the last twelve months and a sizeable net…
Barclays has kept an Equalweight rating and a $68.00 price target on Kroger (KR), describing the appointment of Greg Foran as CEO as an "incremental positive" and characterizing the leadership change as the "best case scenario" given Foran's background and parallels to Walmart at a similar stage of evolution. The bank outlined operational and comme…
Williams Trading raised its price target on Under Armour (NYSE:UAA) to $10.00 from $8.00 and retained a Buy rating, pointing to marketing initiatives designed to build brand loyalty—including a new commercial tied to U.S. Women’s Flag Football—and localized in-store efforts that highlight the company's ties to 3,000 high school football teams. The …
BMO Capital raised its Marathon Petroleum (MPC) price target to $225.00 from $200.00 and kept an Outperform rating after the company reported stronger-than-expected fourth quarter 2025 results and provided optimistic first quarter 2026 guidance. The firm boosted 2026 and later EPS and EBITDA estimates, driven mainly by refining, while trimming its …
BMO Capital raised its price target on Black Hills Corp to $84 from $82 and maintained an Outperform rating, pointing to growing confidence in the utility’s microgrid management fee and potential data center revenue. The firm’s move follows fiscal year results that matched guidance midpoint and 2026 guidance signaling modest earnings growth, even a…
UBS raised its 12-month price objective on CBOE Holdings to $290 from $280 while retaining a Neutral stance. The move comes after the company posted stronger-than-expected trading volumes and quarterly results, prompting upward revisions to UBS's forward estimates even as expected expense reductions tied to business exits have not fully appeared.
Dynatrace reported third-quarter results that beat expectations across key metrics, driving a roughly 9% pre-market increase in the stock. The company delivered above-consensus ARR and revenue growth, maintained healthy unit economics and announced a substantial share-repurchase program expansion while raising full-year fiscal 2026 guidance.
Becton Dickinson (BDX) shares slipped about 5% in pre-market trade after the company reported fiscal Q1 2026 results. While the medical technology firm beat consensus on revenue and adjusted EPS, its fiscal Q2 revenue outlook and ongoing margin questions weighed on investor sentiment. RBC Capital left its Sector Perform rating intact and held a $21…
TD Cowen reaffirmed a Hold rating and a $168 price target for Chevron (CVX), a level below the stock's current trading price and near its 52-week high. The firm emphasized Chevron's emphasis on margin expansion rather than production growth, noted a pause on Venezuela capital allocation for 18-24 months, and highlighted the company’s continued focu…
TD Cowen has reaffirmed a Buy rating and $70.00 price target on Novo Nordisk (NVO) following signals from the FDA that it may clamp down on compounded GLP-1 therapies. The move follows a Department of Justice referral that prompted HIMS to stop selling compounded oral semaglutide. While the development is viewed positively for branded manufacturers…
